<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01515774</url>
  </required_header>
  <id_info>
    <org_study_id>H-1104-062-358</org_study_id>
    <nct_id>NCT01515774</nct_id>
  </id_info>
  <brief_title>Study to Observe the Effect of Mirapex ER® Once-daily (QD) Versus Twice-daily (BID)</brief_title>
  <official_title>An Open-label, Randomized, Multi-center, Crossover Study to Observe the Effect of Once-daily Mirapex ER® and Twice-daily Mirapex ER® in Patients With Parkinson Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seoul National University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      1. In order to observe the benefit, side effects, and patient preference of Mirapex ER when
           used in once-daily (QD) or twice-daily (BID) dosing

        2. In order to estimate the conversion rate of dopamine agonists into Mirapex ER
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      1. Study subjects : Parkinson disease who are on Requip or Mirapex and are considering to
           change into Mirapex ER

        2. Cross over study design:

             -  Group 1: Once daily dose for 2 month then into BID in divided dose for 2 months

             -  Group 2: BID in divided dose for 2 months then into QD dose for 2 months

        3. Dose adjustment may be done in the first 4 weeks.

        4. Compare the benefit, side effects, and patient preference between the QD vs BID dosing
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>September 2011</start_date>
  <completion_date type="Anticipated">October 2012</completion_date>
  <primary_completion_date type="Anticipated">August 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Patient preference</measure>
    <time_frame>4 months</time_frame>
    <description>Overall preference in QD versus BID</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Motor complications</measure>
    <time_frame>2 months at each arm</time_frame>
    <description>Visual rating scale for off severity, dyskinesia severity Duration - off duration, dyskinesia duration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sleep problems</measure>
    <time_frame>2 months at each arm</time_frame>
    <description>Parkinson's disease sleep scale (PDSS) Excessive daytime sleepiness scale(ESS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Motor UPDRS and HY stage</measure>
    <time_frame>2months at each arm</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Side effects</measure>
    <time_frame>2 months at each arm</time_frame>
    <description>Rating scale (0~10): Nausea, Dizziness, Somnolence, Headache, Constipation, Dyspepsia, Fatigue, Hallucination, Edema, Dry mouth,Others</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient global impression for improvement</measure>
    <time_frame>2 months at each arm</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Preference in each factor</measure>
    <time_frame>4 months</time_frame>
    <description>Preference of QD versus BID in each factor: off duration, off severity, dyskinesia duration, dyskinesia severity, on quality, adverse events, sleep quality, convenience</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient choice</measure>
    <time_frame>4 months</time_frame>
    <description>Patient choice in QD or BID Reason for the choice</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Parkinson's Disease</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Give QD dose first then BID dosing</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Give BID dosing and then QD dosing</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mirapex ER</intervention_name>
    <description>Change Requip or Mirapex to Mirapex ER</description>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age: 30-80

          2. Parkinson disease

          3. On dopamine agonists (Requip or Mirapex) and are considering to change into Mirapex ER

          4. On stable antiparkinsonian medication for at least 4 weeks

          5. Who signed consent to the study

        Exclusion Criteria:

          1. Who are on less than 2 mg of Requip or 0.375 mg of Mirapex

          2. Who have dementia, psychosis, major depression and other serious neurological or
             medical problems

          3. Who are allergic to the similar medications

          4. Who has history of heavy metal poisoning

          5. Who were on othe clinical trials of other medications within the last 4 weeks

          6. Who are pregnant or lactating

          7. Who are considered not eligible by the investigator
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Beom S Jeon, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Beom S Jeon, MD, PhD</last_name>
    <phone>82-2-2072-2876</phone>
    <email>brain@snu.ac.kr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ji Young Yun, MD</last_name>
    <phone>82-2-2072-0359</phone>
    <email>dream-yoon@hanmail.net</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>110-744</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Beom S. Jeon, MD, PhD</last_name>
      <phone>82-2-2072-2876</phone>
      <email>brain@snu.ac.kr</email>
    </contact>
    <contact_backup>
      <last_name>Ji Y Yun, MD</last_name>
      <phone>82-2-2072-0359</phone>
      <email>dream-yoon@hanmail.net</email>
    </contact_backup>
    <investigator>
      <last_name>Beom S. Jeon, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Han-Joon Kim, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ji Y Yun, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Young Eun Kim, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <reference>
    <citation>Jenner P, Könen-Bergmann M, Schepers C, Haertter S. Pharmacokinetics of a once-daily extended-release formulation of pramipexole in healthy male volunteers: three studies. Clin Ther. 2009 Nov;31(11):2698-711. doi: 10.1016/j.clinthera.2009.10.018.</citation>
    <PMID>20110012</PMID>
  </reference>
  <reference>
    <citation>Rascol O, Barone P, Hauser RA, Mizuno Y, Poewe W, Schapira AH, Salin L, Sohr M, Debieuvre C; Pramipexole Switch Study Group. Efficacy, safety, and tolerability of overnight switching from immediate- to once daily extended-release pramipexole in early Parkinson's disease. Mov Disord. 2010 Oct 30;25(14):2326-32. doi: 10.1002/mds.23262.</citation>
    <PMID>20669265</PMID>
  </reference>
  <verification_date>January 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 10, 2012</study_first_submitted>
  <study_first_submitted_qc>January 18, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 24, 2012</study_first_posted>
  <last_update_submitted>January 18, 2012</last_update_submitted>
  <last_update_submitted_qc>January 18, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 24, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Seoul National University Hospital</investigator_affiliation>
    <investigator_full_name>BS Jeon</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Parkinson's disease</keyword>
  <keyword>Pramipexole</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pramipexole</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>June 13, 2017</submitted>
    <returned>October 31, 2017</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

